Novo Nordisk's Oral Weight Loss Drug Receives Approval in Europe

Novo Nordisk has received approval in Europe for the first oral weight loss drug. Known as the pill form of Wegovy, this new product expands the company's weight management portfolio. The approval from the European Medicines Agency (EMA) offers patients an oral alternative to injections for obesity treatment. With this approval, Novo Nordisk aims to gain a competitive advantage in the European market. The company had previously achieved significant success with injectable Wegovy. The oral formulation is expected to improve patient compliance and reach a broader user base. Analysts note that this development will strengthen Novo Nordisk's growth potential. Demand in the obesity drug market has accelerated the company's R&D investments. The approval in Europe is considered a key step in the company's global strategy. This is not investment advice.

📊 NVO — Piyasa Yorumu

▲ up · 65%

The news serves as a significant catalyst for Novo Nordisk, as the approval of its oral weight-loss drug in Europe could enhance the company's growth potential. Technically, the stock is trading above its 50-day moving average, with an RSI of 47 in neutral territory, indicating room for upward movement. Although the MACD line remains below the signal line, the 2.3% gain over the past 24 hours suggests positive momentum. In the short term, supported by this news, the stock is likely to rise toward its 20-day average of 50.85.

RSI 14

47.4

MACD

0.17

24h Δ

2.35%

Canlı Grafikler